Lubrizol Acquires Bavaria Medizin Technologie GmbH-LH2

Lubrizol Acquires Bavaria Medizin Technologie GmbH

July 15, 2019

The acquisition expands Lubrizol's medical device design, development and manufacturing capabilities and adds expertise in drug-coated balloons and innovative catheter-based products

CLEVELAND, Ohio -- The Lubrizol Corporation announces the acquisition of Bavaria Medizin Technologie GmbH (BMT), an innovative designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and nonvascular devices, including drug-coated balloons, by its German subsidiary Lubrizol Deutschland GmbH from its current majority shareholder Custos Vermögensverwaltungs GmbH as well as from the minority shareholders.

This acquisition builds upon Lubrizol's expertise in precision thermoplastic extrusion and product development, establishing Lubrizol as a true end-to-end partner to the global medical device and pharmaceutical industries.

With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania. A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath™ catheter. Today, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. Additionally, BMT offers private label manufacturing of proprietary catheters and balloons along with original equipment manufacturing (OEM) services, which include the manufacturing of subassemblies and components, sterilization, packaging and labeling, stent crimping, and logistics management.

The acquisition of BMT expands Lubrizol's product design, development, and manufacturing expertise and provides access to proprietary catheter and balloon technologies. BMT's experience and reputation in the drug-coated balloon (DCB) space aligns well with Lubrizol's pharmaceutical CDMO business and positions Lubrizol as the ideal partner for developing next generation DCBs.

"Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space," said Uwe Winzen, general manager of the Health business of Lubrizol Life Science. "Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services."

For more information on Lubrizol Life Science medical device contract manufacturing, visit www.lubrizol.com/Health.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway Company, leverages its unmatched science to unlock immense possibilities at the molecular level, driving sustainable and measurable results. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has approximately 8,600 employees. For more information, visit www.Lubrizol.com.

News Categories: <a href=/Newscenter/News-and-Insights?category=Corporate>Corporate</a>, <a href=/Newscenter/News-and-Insights?category=Health>Health</a>

Media Contacts

Amanda O'Neil

+1 216-447-5020

amanda.oneil@lubrizol.com